Literature DB >> 19812195

Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease.

Hemant Agrawal1, Noam Jacob, Esther Carreras, Sandra Bajana, Chaim Putterman, Sean Turner, Barbara Neas, Alexis Mathian, Michael N Koss, William Stohl, Susan Kovats, Chaim O Jacob.   

Abstract

Type I IFNs are potent regulators of innate and adaptive immunity and are implicated in the pathogenesis of systemic lupus erythematosus. Here we report that clinical and pathological lupus nephritis and serum anti-nuclear Ab levels are greatly attenuated in New Zealand Mixed (NZM) 2328 mice deficient in type I IFN receptors (IFNAR). To determine whether the inflammatory environment in NZM 2328 mice leads to IFNAR-regulated changes in dendritic cells (DC), the number, activation, and function of DC subsets were compared in 2- and 5-mo-old (clinically healthy) female NZM and NZM-IFNAR(-/-) mice. Numbers of activated CD40(high) plasmacytoid DC (pDC) were significantly increased in renal lymph nodes of 2-mo-old NZM but not NZM-IFNAR(-/-) mice, suggesting an early IFNAR-dependent expansion and activation of pDC at disease sites. Relative to NZM spleens, NZM-IFNAR(-/-) spleens in 5-mo-old mice were significantly decreased in size and contained reduced numbers of conventional DC subsets, but not pDC. Splenic and renal lymph node NZM-IFNAR(-/-) DC analyzed directly ex vivo expressed significantly less CD40, CD86, and PDL1 than did NZM DC. Upon activation with synthetic TLR9 ligands in vitro, splenic NZM-IFNAR(-/-) DC produced less IL-12p40/70 and TNF-alpha than did NZM DC. The limited IFNAR(-/-) DC response to endogenous activating stimuli correlated with reduced numbers of splenic activated memory CD4(+) T cells and CD19(+) B cells in older mice. Thus, IFNAR signaling significantly increases DC numbers, acquisition of Ag presentation competence, and proinflammatory function before onset of clinically apparent lupus disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812195      PMCID: PMC2766036          DOI: 10.4049/jimmunol.0803872

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice.

Authors:  Déborah Braun; Pedro Geraldes; Jocelyne Demengeot
Journal:  J Autoimmun       Date:  2003-02       Impact factor: 7.094

2.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.

Authors:  Mikhail B Litinskiy; Bernardetta Nardelli; David M Hilbert; Bing He; Andras Schaffer; Paolo Casali; Andrea Cerutti
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

3.  Lymphoid precursors are directed to produce dendritic cells as a result of TLR9 ligation during herpes infection.

Authors:  Robert S Welner; Rosana Pelayo; Yoshinori Nagai; Karla P Garrett; Todd R Wuest; Daniel J Carr; Lisa A Borghesi; Michael A Farrar; Paul W Kincade
Journal:  Blood       Date:  2008-06-13       Impact factor: 22.113

4.  Type I interferons produced by dendritic cells promote their phenotypic and functional activation.

Authors:  Maria Montoya; Giovanna Schiavoni; Fabrizio Mattei; Ion Gresser; Filippo Belardelli; Persephone Borrow; David F Tough
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

5.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

Review 6.  The interplay of dendritic cell subsets in systemic lupus erythematosus.

Authors:  A Karolina Palucka; Jacques Banchereau; Patrick Blanco; Virginia Pascual
Journal:  Immunol Cell Biol       Date:  2002-10       Impact factor: 5.126

7.  IFNalpha activates dormant haematopoietic stem cells in vivo.

Authors:  Marieke A G Essers; Sandra Offner; William E Blanco-Bose; Zoe Waibler; Ulrich Kalinke; Michel A Duchosal; Andreas Trumpp
Journal:  Nature       Date:  2009-02-11       Impact factor: 49.962

8.  Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion.

Authors:  Taku Sato; Nobuyuki Onai; Hiroki Yoshihara; Fumio Arai; Toshio Suda; Toshiaki Ohteki
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

9.  Increased circulating CD11b+CD11c+ dendritic cells (DC) in aged BWF1 mice which can be matured by TNF-alpha into BLC/CXCL13-producing DC.

Authors:  Sho Ishikawa; Shigenori Nagai; Taku Sato; Kenji Akadegawa; Hiroyuki Yoneyama; Yan-Yun Zhang; Nobuyuki Onai; Kouji Matsushima
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

10.  Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.

Authors:  Lynda Bennett; A Karolina Palucka; Edsel Arce; Victoria Cantrell; Josef Borvak; Jacques Banchereau; Virginia Pascual
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  79 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 3.  Impaired clearance of apoptotic cells in germinal centers: implications for loss of B cell tolerance and induction of autoimmunity.

Authors:  Ziaur S M Rahman
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

4.  Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; Shunhua Guo; Laurence Morel
Journal:  Arthritis Rheum       Date:  2010-08

5.  TLR7-Mediated Lupus Nephritis Is Independent of Type I IFN Signaling.

Authors:  Sonya J Wolf; Jonathan Theros; Tammi J Reed; Jianhua Liu; Irina L Grigorova; Giovanny Martínez-Colón; Chaim O Jacob; Jeffrey B Hodgin; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2018-06-08       Impact factor: 5.422

6.  A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus.

Authors:  Peng Du; Lei Xu; Weiyi Qiu; Dadi Zeng; Junjie Yue; Shuang Wang; Peitang Huang; Zhiwei Sun
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1.

Authors:  Jianhua Liu; Celine C Berthier; J Michelle Kahlenberg
Journal:  Arthritis Rheumatol       Date:  2017-08-08       Impact factor: 10.995

Review 8.  Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future.

Authors:  Noam Jacob; William Stohl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

9.  Type I interferon receptor deficiency prevents murine Sjogren's syndrome.

Authors:  B M Szczerba; P D Rybakowska; P Dey; K M Payerhin; A B Peck; H Bagavant; U S Deshmukh
Journal:  J Dent Res       Date:  2013-03-26       Impact factor: 6.116

10.  Nucleic acid-containing amyloid fibrils potently induce type I interferon and stimulate systemic autoimmunity.

Authors:  Jeremy Di Domizio; Stephanie Dorta-Estremera; Mihai Gagea; Dipyaman Ganguly; Stephan Meller; Ping Li; Bihong Zhao; Filemon K Tan; Liqi Bi; Michel Gilliet; Wei Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.